Emergent Biosolutions Inc
Emergent Biosolutions Inc/ US29089Q1058 /
EBS
2024-04-17 10:10:00 PM
|
Chg.
-0.05
|
Volume |
Bid2:00:00 AM |
Ask2:00:00 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
1.90USD
|
-2.56%
|
692,033 Turnover: 1.2 mill. |
1.87Bid Size: 100 |
1.92Ask Size: 700 |
99.19 mill.USD |
- |
- |
Business description
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life.
Management board & Supervisory board
CEO |
Robert G. Kramer |
Management board |
Richard S. Lindahl, Adam R. Havey, Atul Saran, Dr. Karen L. Smith, Fuad El-Hibri, Katy Strei |
Supervisory board |
Fuad El-Hibri, Dr. Jerome M. Hauer, Dr. Kathryn C. Zoon, Dr. Zsolt Harsanyi, General George A. Joulwan, Louis W. Sullivan, Marvin White, Robert G. Kramer, Sr., Ronald B. Richard |
Company data
Name: |
Emergent Biosolutions Inc. |
Address: |
400 Professional Drive,Gaithersburg , Maryland 20879, USA |
Phone: |
+1-301-795-1800 |
Fax: |
+1-301-795-1899 |
E-mail: |
-
|
Internet: |
www.emergentbiosolutions.com/ |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12-31 |
Free Float: |
75.10% |
IPO date: |
- |
Investor relations
Name: |
Robert G. Burrows |
IR phone: |
+1-240-631-3280 |
IR Fax: |
- |
IR e-mail: |
BurrowsR@ebsi.com
|
Main Shareholders
Freefloat |
|
75.10% |
BlackRock, Inc. |
|
10.00% |
Vanguard Group, Inc. |
|
8.90% |
Neuberger Berman entities |
|
6.00% |